Treatment with Activated Protein C (aPC) Is Protective during the Development of Myocardial Fibrosis: An Angiotensin II Infusion Model in Mice

Sopel Mryanda J.
Rosin Nicole L.
Falkenham Alec G.
Bezuhly Michael
Esmon Charles T.
Lee Timothy D. G.
Liwski Robert S.
Légaré Jean-Francois

Open link

Publication date

September 2012

DOI

10.1371/journal.pone.0045663

Publisher

Public Library of Science

Abstract

Myocardial fibrosis contributes to the development of heart failure. Activated Protein C (aPC) is a circulating anticoagulant with anti-inflammatory and cytoprotective properties. Using a model of myocardial fibrosis second to Angiotensin II (AngII) infusion, we investigated the novel therapeutic function aPC in the development of fibrosis.<0.01). AngII-aPC infusion inhibited this cellular infiltration and the corresponding collagen deposition. AngII-aPC infusion also inhibited significant expression of the pro-fibrotic cytokines TGF-β1, CTGF and PDGF found in AngII only infused animals (p<0.05). aPC signals through its receptor, EPCR. Using Tie2-EPCR animals, where endothelial cells over-express EPCR and exhibit enhanced aPC-EPCR signaling...

Extracted data

We use cookies to provide a better user experience.

Data Protection

Treatment with Activated Protein C (aPC) Is Protective during the Development of Myocardial Fibrosis: An Angiotensin II Infusion Model in Mice

Abstract

Extracted data

Treatment with Activated Protein C (aPC) Is Protective during the Development of Myocardial Fibrosis: An Angiotensin II Infusion Model in Mice

Abstract

Extracted data

Related items

Related items